PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Klockner Pentaplast announces plans for New Lamination Facility

Montabaur, Germany – June 7, 2016 – The Klöckner Pentaplast Group announced plans today to expand its high-barrier film lamination and coating capacities to reinforce the company’s commitment to the global pharmaceutical and medical industries. Beginning in early 2017, Klöckner Pentaplast will use a state-of-the-art system to produce Aclar® laminated pharmaceutical films from its site in Montabaur, Germany, a trusted source of high quality kp films for many industries. The new Montabaur line will be fully operational for the entire kp Pentapharm® Aclar® product range by the end of 2017.
As a result of this investment, the Klöckner Pentaplast facility in Bern, Switzerland will also have added capacity available to produce PVdC-coated high-barrier pharmaceutical films, while continuing to be a backup site for Aclar® lamination. The plan strengthens kp’s dedication to its global packaging customers by providing improved customer service and security of supply from multiple sites under a global DMF.
“This capacity expansion is part of Klöckner Pentaplast’s long-term strategy to leverage our global footprint to maximize improvements across the value chain, with a focus on being even more responsive to our pharmaceutical customers’ needs now and in the future,“ says Markus Pischulti, Business Director, Pharmaceutical Films EMEA.
 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026